LEGN

Insider Trades

Name	Value	Action	Price	Current Price
Huang YingDirector, Officer: Chief Executive Officer $87k9.9k shares SellMar 25, 2026 $8.77 --

News

benzinga.comLegend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionbenzinga.comJun 18

globenewswire.comLegend Biotech Corporation Announces Pricing of Public Offeringglobenewswire.comJun 17

globenewswire.comLegend Biotech Corporation Announces Proposed Public Offeringglobenewswire.comJun 17

globenewswire.comLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphomaglobenewswire.comJun 15

Trade LEGN

About Legend Biotech Corporation

Legend Biotech Corporation is a clinical-stage biopharmaceutical firm, operating through its various subsidiaries, dedicated to the discovery and advancement of innovative cell therapies. These treatments primarily target oncological conditions but also address other diseases across the United States, China, and international markets. The company's most advanced investigational therapy is LCAR-B38M, a chimeric antigen receptor (CAR) product specifically developed for treating multiple myeloma (MM). This lead candidate is currently undergoing comparative evaluation against standard triplet therapies in patients suffering from revlimid-refractory multiple myeloma. Additionally, Legend Biotech possesses a pipeline of early-stage, autologous product candidates, which are presently in Phase I clinical trials for addressing gastric cancer and T-cell lymphoma. The company is also actively developing CAR-T cell therapies designed to target CD20, CD22, and CD19 for the treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further expanding its therapeutic scope, the firm has product candidates in both early preclinical and clinical development phases aimed at solid tumors and infectious diseases. A significant collaboration exists with Janssen Biotech, Inc., for the joint development and commercialization of ciltacabtagene autoleucel. Founded in 2014, Legend Biotech Corporation is based in Somerset, New Jersey, and functions as a subsidiary of Genscript Biotech Corporation.

CEO: Ying Huang
IPO Date: Jun 5, 2020

Market Data

Open: $29.66
High: $29.80
Low: $27.43
Volume: 13.6M
Avg Volume: 2.6M
52W High: $45.30
52W Low: $16.24

Valuation

Market Cap: $5.2B
Enterprise Value: $4.9B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-168M
Revenue: $1.0B
Net Income: $-297M
Cash: $902M
Debt: $414M

Events

EarningsAug 10

EPS est. 0.12